Lenalidomide is a second-generation immunomodulatory drug that has been approved to treat relapsed or refractory multiple myeloma. Here, we describe a patient who was treated with a low dose of lenalidomide (5 mg/day on days 1-21 of a 28-day cycle) because the standard dose of bortezomib was too toxic and adverse events persisted. However, he developed fever, dyspnea, hypoxia and pulmonary infiltrates. The results of an extensive workup for other causes including infections were negative and the final diagnosis was lenalidomide-induced interstitial pneumonitis. This is the first case report of lenalidomide-induced pneumonitis in a Japanese patient. Criteria, version 3) developed. As MM gradually deteriorated, he was started on lenalidomide (5 mg/day on days 1-21 of a 28-day cycle) and dexamethasone (4 mg weekly) in July 2011. Although he had good renal function, lenalido-
Introduction
The introduction of agents such as thalidomide, bortezomib and lenalidomide has significantly improved the outcome of patients with multiple myeloma (MM) (1) . The combination of lenalidomide and dexamethasone for patients with MM who had already undergone one course of therapy was approved by the U.S. Food and Drug Administration on June 29, 2006, and by the Japanese Ministry of Health, Labour and Welfare on June 25, 2010. Common side effects of lenalidomide treatment include myelosuppression, diarrhea, fever, muscle cramps, neuropathy, constipation, rash, fatigue and deep vein thrombosis (2) (3) (4) . Although pulmonary toxicity is considered rare, lenalidomide-associated pneumonitis has been described (5) (6) (7) (8) (9) . All patients described in these reports received the standard dose of lenalidomide. Here, we describe a patient with MM who developed fever, dyspnea, and pulmonary infiltrates while under low-dose lenalidomide. This is the first description of lenalidomide-induced pneumonitis arising in a Japanese patient.
Case Report
A 66-year-old Japanese man with no particular medical history was diagnosed in December 2008 with MM Bence Jones lambda stage IIIA according to the Durie Salmon staging system. He was treated with three cycles of melphalan and prednisolone (MP) without significant toxicity, and the plateau phase of the disease was achieved. However, progressive MM developed during October 2009 and deteriorated despite two more cycles of MP in March 2010. He was treated in May 2010 with bortezomib (1.3 mg/m 2 i.v. on days 1, 4, 8 and 11) combined with dexamethasone (9.9 mg on days 1, 2, 4, 5, 8, 9, 11 and 12) , which resulted in a very good partial response. However, bortezomib had to be discontinued after two cycles because grade 3 peripheral sensory and motor neuropathy, neuralgia and grade 4 thrombo- mide was started at a reduced dose of 5 mg because the previous standard dose of bortezomib therapy was too toxic and the resulting grade 2 peripheral sensory neuropathy and neuralgia had persisted. The dose of dexamethasone was accordingly adjusted considering adverse effects.
Fatigue, slight fever and increasing numbness developed on day 12 of therapy. Room air pulse oximetry was normal. A chest examination revealed the absence of rales, regular heart sounds without murmurs or gallops and a he did not have a skin rash. Fever developed and fatigue worsened after three days. Chest radiography revealed reticular opacity in the right upper lung field, which had not been evident at the time of starting lenalidomide ( Fig. 1A, B ). Oxygen saturation decreased to 89% in ambient air. Rales were absent. Lenalidomide was discontinued due to the possibility of pulmonary drug toxicity. Laboratory tests revealed a WBC count of 2,000/μL with 42% neutrophils, 13.0% eosinophils, 29% lymphocytes, 16% monocytes, hemoglobin 7.7 g/dL, platelets 81,000/μL, CRP 3.09 mg/dL, LDH 304 IU/L, Bnatriuretic peptide 141.6 pg/mL, beta-D-glucan 11.6 pg/mL, KL-6 891 U/mL, SP-D 93.7 ng/mL and SP-A 121.0 ng/mL ( Table 1 ). Blood and urine cultures were analyzed. Cefozopran i.v. treatment for seven days resulted in minimal clini-cal improvement and progressive hypoxia (pH, 7.401; PO2, 68.1 Torr; PCO2, 35.1 Torr; nasal cannula O2, 3 L/min). All culture results were negative. Chest radiography revealed that the shadow had progressed ( Fig. 1C ) and plain chest CT likewise showed progression of the reticular opacities, ground-glass opacity and right pleural effusion ( Fig. 2A) . The left lung field appeared normal, swallowing function was competent and a risk of aspiration pneumonia was absent. A transbronchial lung biopsy (TBLB) was taken from the right B3a bronchus and bronchoalveolar lavage (BAL) was performed using 200 mL of sterile saline (recovery rate, 111 (55.5%) mL) from the right B3b. The white cell count in the BAL fluid (BALF) was 3.0×10 5 /mL and comprised 39.0% lymphocytes, 8.0% eosinophils, 4.0% neutrophils and 48.0% macrophages. The T-cell subset in BALF analyzed by flow cytometry was: 54% CD3, 38% CD4, 21% CD8, 0.0% CD19 and the CD4/CD8 ratio was 1.81. The TBLB specimen showed lymphocytic infiltration of the alveolar spaces and interstitium ( Fig. 3 ). Microbial cultures obtained from BALF provided no evidence of bacterial or fungal pathogens. Grocott stain of the BALF was negative for Pneumocystis jiroveci and other fungal agents. The results of a polymerase chain reaction (PCR) study of BALF were negative for cytomegalovirus, Pneumocystis jiroveci, tuberculosis and mycobacterium avium complex. Because discontinuing lenalidomide did not result in spontaneous regression of his symptoms, we administered prednisolone (0.8 mg/kg) 10 days after stopping lenalidomide to treat lenalidomideinduced pneumonitis. This strategy remarkably improved the subjective symptoms and chest imaging findings ( Fig. 1D , 2B) after one week and laboratory tests revealed a decrease in eosinophils and CRP and a slight decrease in KL-6, SP-D and SP-A. Tapering of the prednisolone dose over a period of one month did not result in relapse. Although drug-induced lymphocyte stimulation tests (DLST) for lenalidomide with both peripheral blood and BALF were negative, the clinical course indicated lenalidomide-induced interstitial pneumonitis. His medications at that time included clonazapam, pregabalin, mecobalamin and tramadol mainly to treat peripheral sensory neuropathy and neuralgia. These medications were started before admission to hospital and not changed. Therefore, we suspected that lenalidomide might have caused interstitial changes in the lung. Cefozopran was started after stopping lenalidomide and continued in parallel with prednisolone therapy. The steroid therapy with cefozopran was so effective that this medication was not considered to have caused the lung toxicity. Although he remained free of relapse for one month after stopping prednisolone, he died due to progressive primary disease.
Discussion
Patients with hematological malignancies can develop innumerable pulmonary manifestations as complications of either the disease or diverse therapeutic agents (10) . The clinical manifestations of antineoplastic-associated pneumonitis are nonspecific and include fever, dyspnea, chest pain, sputum production, hemoptysis, hypoxemia, leukocytosis and pulmonary infiltrates. Antineoplastic-associated pneumonitis is diagnosed by exclusion. The differential is broad, including pulmonary involvement from the underlying condition and opportunistic infections. Fiberoptic bronchoscopy with BAL is essential to exclude infectious etiologies (11) .
Lenalidomide is the first of a new class of immunomodulatory agents that is chemically similar to thalidomide (1-3). A growing body of evidence has linked lenalidomide and thalidomide to potential pulmonary toxicity. A review of the literature revealed four case reports and one summary of eight patients with lenalidomide-associated pneumonitis (5-9) ( Table 2 ). The most common presenting symptoms in these reports were fever, fatigue and dyspnea, which were consistent with those of the present patient. Symptoms start to develop between treatment cycles 1 and 3. Zagouri et al. (9) reported that the median duration required for lenalidomide-induced pneumonitis to become symptomatic is about 3-5 months. Respiratory symptoms developed in the formation (B, arrow). (A, ×100; B, ×200) .
present patient on day 12 after starting lenalidomide, which was the earliest of all such reported patients. The pulmonary toxicity in our patient was considered to result from an allergic or immunological reaction of the lung to lenalidomide from the following viewpoints. First, adverse events occurred over a short term on a minimal dose. Secondly, events were characterized by eosinophilia and lymphocytosis in BALF. Thirdly, although the pulmonary infiltrates did not subside after drug withdrawal, steroid therapy exerted an immediate clinical benefit. Our patient was initially treated with dexamethasone and low-dose lenalidomide (5 mg/day on days 1-21 of a 28-day cycle) because bortezomib therapy had resulted in powerful and prolonged side effects (persistent grade 2 peripheral sensory neuropathy). We planned to cautiously increase the dose of lenalidomide to avoid severe adverse effects. Whether or not the reduced dose of dexamethasone was associated with the development of lenalidomide-induced pneumonitis is uncertain. The most common radiological finding was ground-glass opacities. Chest plain CT in our patient revealed obvious thickening of the interlobular septa in the right upper lobe besides the ground-glass opacities. Bronchoscopy with BAL and TBLB are useful for distinguishing infection from drug-induced inflammation (11) . Most of the reported patients did not respond to empirical antibiotics but later responded well to lenalidomide withdrawal regardless of the presence or absence of high-dose corticosteroid. None of the conditions were life-threatening and all were reversible. Although discontinuing lenalidomide caused the condition of our patient to gradually worsen, corticosteroid resolved the lung infiltrates on chest radiographs within one week. Repeated challenge followed by recurrence is central to a diagnosis of druginduced pneumonitis but it is seldom intentionally applied because of the inherent risk of death associated with rechallenge (12) . The reintroduction of a reduced drug has caused recurrent pneumonitis in one patient (5) . We did not undertake a re-challenge for our patient in order to avoid aggravating his condition. Because the histopathological features vary, a lung biopsy (clinical status permitting) might be required for a subset of patients with suspected drug-induced pneumonitis, because histopathological findings might help to rule out infection and determine whether the pulmonary reaction is appropriate for a particular drug (11). Vahid and Marik (10) have classi-fied antineoplastic agent-associated infiltrative lung diseases in patients with hematological malignancies into eight groups based on the clinical and pathological manifestations of nonspecific interstitial pneumonitis/fibrosis, organizing pneumonia, desquamative interstitial pneumonia, eosinophilic pneumonia, granulomatous pneumonitis (hypersensitivity-like pneumonitis), noncardiogenic pulmonary edema and acute respiratory distress syndrome, diffuse alveolar hemorrhage and retinoic acid syndrome. Only one case report (7) has presented TBLB findings of lymphohistiocytic interstitial inflammation and granulomatous features, which are typical of hypersensitivity-like pneumonitis. The TBLB specimen from the present patient revealed infiltrating lymphocytes and monocytes in the interstitium but granuloma was absent and intraluminal polypoid plugs of loose organizing connective tissue indicated the classic profile of organizing pneumonia. The histological findings were considered to represent the process of lung tissue repair.
Several reports have indicated a higher incidence of drugassociated pulmonary complications among Japanese patients than in patients from other countries (13, 14) . This tendency has also been associated with thalidomide and bortezomib (15, 16) . One pharmaceutical manufacturer (Celgene Corporation) has surveyed the outcomes of lenalidomide for a reexamination application in Japan. Among 4,314 patients who participated in the survey as of August 31, 2011, 33 (0.76%) of them experienced lenalidomideinduced pneumonitis, which was similar to a previous safety profile of lenalidomide (4). This is the first case report of a Japanese patient with multiple myeloma who developed lenalidomide-induced pneumonitis that was successfully treated by discontinuing lenalidomide and corticosteroid. Physicians should be cognizant of potential pulmonary toxicity in patients undergoing lenalidomide therapy because even a low dose can cause drug-induced pneumonitis.
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